

10/795,863

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:54:32 ON 31 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jan 2007 VOL 146 ISS 6


FILE LAST UPDATED: 30 Jan 2007 (20070130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 6 SEA FILE=REGISTRY SSS FUL L1

L4 1 SEA FILE=CAPLUS L3

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:756707 CAPLUS

DOCUMENT NUMBER: 141:277497

TITLE: Preparation of benzoylureidopyridylpiperidines for the treatment of type 2 diabetes

INVENTOR(S): Schoenafinger, Karl; Kadereit, Dieter; Defossa, Elisabeth; Herling, Andreas; Klabunde, Thomas

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004078743      A1      20040916      WO 2004-EP1735      20040221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10309929      A1      20041202      DE 2003-10309929      20030307

DE 10309929      B4      20060223

AU 2004218267      A1      20040916      AU 2004-218267      20040221

CA 2518322      A1      20040916      CA 2004-2518322      20040221

EP 1603895      A1      20051214      EP 2004-713467      20040221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004008148      A      20060301      BR 2004-8148      20040221

CN 1759109      A      20060412      CN 2004-80006240      20040221

JP 2006519795      T      20060831      JP 2006-504448      20040221


US 2004266768      A1      20041230      US 2004-795863      20040308

NO 2005004418      A      20050923      NO 2005-4418      20050923


PRIORITY APPLN. INFO.:      DE 2003-10309929      A      20030307

GI      US 2003-487497P      P      20030715


OTHER SOURCE(S):      MARPAT 141:277497      WO 2004-EP1735      A      20040221



I



II



III

AB Title compds. I [R1, R2 = H, halo, alkyl, etc.; R3 = H, alkyl, O-alkyl, etc.; X = OH, O-alkyl, NH2, etc.; A, B, D, E = CH, N, with the proviso that one of A, B, D or E is N; Y = (CH2)m; m = 0-2] and their pharmaceutically acceptable salts were prepared. For example, condensation of amine II, e.g., prepared from 2-chloro-3-nitropyridine in 2-steps, and

10/795,863

2-chloro-4-fluorobenzoylisocyanate, afforded ureidopyridylpiperidine III. In activated glycogen phosphorylase inhibition assays, 4-examples of compds. I exhibited IC<sub>50</sub> values ranging from 0.01-3.65  $\mu$ M, the IC<sub>50</sub> value of benzoylurea III was 0.04  $\mu$ M. Compds. I were claimed useful for the treatment of type 2 diabetes.


IT 758720-48-8P 758720-49-9P 758720-50-2P  
758720-51-3P 758720-52-4P 758720-53-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzoylureidopyridylpiperidines for the treatment of type 2 diabetes)


RN 758720-48-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-49-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 758720-50-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

COC(=O)N1CCN(CC1)c2ccc(NC(=O)Nc3cc(Cl)c(F)c(F)c3)cc2NC(=O)C1CCN(C1)c2ccc(NC(=O)NC(=O)c3cc(Cl)c(F)c(F)c3)cc2OCCNCC(=O)N1CCCN(C1)c2ccc(NC(=O)Nc3cc(Cl)c(F)c(F)c3)cc2

RN	758720-53-5	CAPLUS	
CN	4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl) amino] carbonyl] amino]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)		

10/795,863



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 14:55:07 ON 31 JAN 2007


CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:55:07 ON 31 JAN 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 6 SEA FILE=REGISTRY SSS FUL L1

L5 1 SEA L3

=> d l5 ibib abs hitstr

L5 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2004:335674 USPATFULL

TITLE: Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use

INVENTOR(S): Schoenafinger, Karl, Alzenau, GERMANY, FEDERAL REPUBLIC OF  
Kadereit, Dieter, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
Defossa, Elisabeth, Idstein, GERMANY, FEDERAL REPUBLIC OF  
Herling, Andreas, Bad Camberg, GERMANY, FEDERAL REPUBLIC OF  
Klabunde, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

NUMBER KIND DATE

10/795,863

PATENT INFORMATION: US 2004266768 A1 20041230  
APPLICATION INFO.: US 2004-795863 A1 20040308 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10309929	20030307
	US 2003-487497P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	703	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to compounds of the formula I ##STR1##

where the radicals are as defined, and their physiologically tolerated salts. The compounds are suitable, for example, as medicaments for preventing and treating type 2 diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 758720-48-8P 758720-49-9P 758720-50-2P

758720-51-3P 758720-52-4P 758720-53-5P

(preparation of benzoylureidopyridylpiperidines for the treatment of type 2 diabetes)


RN 758720-48-8 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-49-9 USPATFULL


CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



10/795,863


RN 758720-50-2 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 758720-51-3 USPATFULL

CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-52-4 USPATFULL


CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



10/795,863

RN 758720-53-5 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)



=>